Seeking Alpha

Myriad Genetics (MYGN) signs an agreement with Cephalon, a subsidiary of Teva Pharmaceutical...

Myriad Genetics (MYGN) signs an agreement with Cephalon, a subsidiary of Teva Pharmaceutical (TEVA), to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study. Myriad has entered into similar agreements with Abbott (ABT), Astra Zeneca (AZN) and BioMarin (BMRN) to provide similar diagnostic testing.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|